PF-00835231

Catalog No.S9731 Batch:S973101

Technical Data

Formula

C₂₄H₃₂N₄O₆

Molecular Weight

472.53

CAS No.

870153-29-0

Solubility (25°C)*

In vitro

DMSO

95 mg/mL (201.04 mM)

Ethanol

95 mg/mL (201.04 mM)

Water

Insoluble

In vivo (Add solvents to the product individually and in order)

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.750mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 95 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.590mg/ml (1.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 11.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

PF-00835231 is a 3CL^pro (M^pro) inhibitor that may targets SARS-CoV-2 protease 3CL^pro as a potential new treatment for COVID-19.

Targets

3CL^pro ^[1]

In vitro

A time-of-drug-addition approach delineates the timing of early SARS-CoV-2 life cycle steps in A549^+ACE2 cells and validates PF-00835231's early time of action. In a model of the human polarized airway epithelium, this compound potently inhibits SARS-CoV-2 at low micromolar concentrations. It exhibits the potential as an effective SARS-CoV-2 antiviral.

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines A549 cells, human airway epithelial cultures (HAEC) Concentrations 1 nM-10 μM Incubation Time 0-4 h Method A549^+ACE2 cells are seeded into black wall 96-well plates at 70% confluency. The next day, media is removed and replaced with complete media containing compound (PF-00835231)/carrier two hours prior to infection. Cells are then infected at 0.425 multiplicity of infection (MOI), based on Vero E6 titer, at 37°C. 1 hour post virus addition, virus is removed, and media containing this compound/carrier is added. At 24 and 48 hours post infection, cells are fixed by submerging in 10% formalin solution for 30-45 min. After fixation, cells are washed once with H2O to remove excess formalin.

Cell Assay:^{^[1]}

Cell lines
A549 cells, human airway epithelial cultures (HAEC)
Concentrations
1 nM-10 μM
Incubation Time
0-4 h
Method
A549^+ACE2 cells are seeded into black wall 96-well plates at 70% confluency. The next day, media is removed and replaced with complete media containing compound (PF-00835231)/carrier two hours prior to infection. Cells are then infected at 0.425 multiplicity of infection (MOI), based on Vero E6 titer, at 37°C. 1 hour post virus addition, virus is removed, and media containing this compound/carrier is added. At 24 and 48 hours post infection, cells are fixed by submerging in 10% formalin solution for 30-45 min. After fixation, cells are washed once with H2O to remove excess formalin.

References

https://pubmed.ncbi.nlm.nih.gov/33622961/

Selleck's PF-00835231 Has Been Cited by 7 Publications

Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for SARS-CoV-2 3CL Protease [ bioRxiv, June 06, 2022, nan]	PubMed: nan
Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors [ Current Issues in Molecular Biology, January 28, 2026, 142]	PubMed: 41751406
Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells [ Mol Cell, 2022, S1097-2765(22)00433-6]	PubMed: 35594856
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease [ Journal of Medicinal Chemistry, 2022, 13852-13865]	PubMed: 36229406
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors [ Bioorg Med Chem Lett, 2022, 66:128732]	PubMed: 35427739
Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates [ Nat Commun, 2021, 12(1):6786]	PubMed: 34811361
Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery [ Front Pharmacol, 2021, 12:773198]	PubMed: 34938188

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.